フィラナ・セラピューティクス
Filana Therapeutics, Inc.
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.18 | $0 | -$4M |
| 2026 Q1 | -0.21 | $0 | — |
| 2025 Q4 | -0.26 | $0 | -$10M |
| 2025 Q3 | -0.22 | $0 | -$6M |
| 2025 Q2 | -0.92 | $0 | — |
| 2025 Q1 | -0.48 | $0 | -$11M |
| 2024 Q4 |
| -0.57 |
| $0 |
| -$61M |
| 2024 Q3 | -0.58 | $0 | -$18M |